



Discover what's new in Cortellis Competitive Intelligence

Claudia Haas, Monica Romero & Rob Provines | November 2025

What is Cortellis Competitive Intelligence?

Global pipeline and competitor data, from discovery to launch:



100K+
pipeline
products



5,500+ products
with orphan drug
designation



300K+ company
profiles



1,400+ drug level
SWOT analyses



Updated
daily




**Hundreds of industry
& scientific experts**



New search interface

New search interface

Faster, easier access to valuable data with more relevant search suggestions and synonyms




Start typing and select relevant terms from the list of suggestions

Icons indicate search result categories

Access Drug and Company reports with a single click

Synonyms (i.e. metformin) are listed below search terms

New search interface





New search results page

New search results page

A modern, intuitive layout, with quicker access to key filters, customizable tables and more

Run your search and click the [Switch to new view](#) button in the upper right to access the new search results page

The screenshot shows the Cortellis search results page for the query "multiple myeloma". The interface includes a search bar at the top with the query and a "Search" button. Below the search bar is a navigation menu with options: Drugs, Deals, Clinical trials, Companies, Patents, and More. A callout box labeled "Switch to different report types" points to the "More" dropdown. Below the navigation menu, the search results are displayed as a table with 1,148 results. The table has columns for Drug name, Highest status, Other drug name, Originator company, Active company, and Therapy area. A callout box labeled "Quick access to key filters" points to the filter controls above the table, which include dropdowns for "Drugs with...", "Status", "Indication", and "Technology", along with "All filters" and "Columns" buttons. The table lists several drugs, including NMP (oral, cancer), histone lysine methyltransferase NSD2 inhibitors (cancer), KB-9558, gintemetostat D-tartrate, and KTX-1029, each with its status (Clinical, Discovery, Preclinical, Phase 1 Clinical) and other details. A "Support" button is visible in the bottom right corner.

1,148 drug results [Show search query](#) [Timeline & Success Rates](#) [Export](#) [Save and Alert](#)

[Drugs with...](#) [Status](#) [Indication](#) [Technology](#) [All filters](#) [Columns](#)

<input type="checkbox"/> Drug name	Highest status	Other drug name	Originator company	Active company	Therapy area
<input type="checkbox"/> NMP (oral, cancer), Peter MacCallum Cancer Centre	Clinical	N-methyl-2-pyrrolidone N-methylpyrrolidone compou... +more	Peter MacCallum Cancer Centre (Australia)	Peter MacCallum Cancer Centr...	Cancer
<input type="checkbox"/> histone lysine methyltransferase NSD2 inhibitors (cancer), Inventiva	Discovery	histone lysine methyltransfera...	Inventiva SA (France)	Inventiva SA (France)	Cancer
<input type="checkbox"/> KB-9558	Preclinical	KB-528 KB-9558	Kronos Bio Inc (US)	Concentra Biosciences LLC (US)	Cancer
<input type="checkbox"/> gintemetostat D-tartrate	Phase 1 Clinical	KTX-1001 KTX-1031 +more	Novartis Pharmaceuticals Corp (US)	K36 Therapeutics Inc (US)	Cancer
<input type="checkbox"/> KTX-1029	Preclinical	KTX-1029	K36 Therapeutics Inc (US)	K36 Therapeutics Inc (US)	Cancer

[Support](#)

New search results page

The screenshot shows the Cortellis search results page for the query "multiple myeloma". The page displays 1,148 drug results. Key features highlighted include:

- Drugs with... filter:** A dropdown menu for filtering drugs based on specific information like SWOT analysis, Market landscape, Chemical structure, Safety intelligence, Sales forecast data, and No deals.
- All filters section:** A central section providing easy access to various filter groups such as Status, Action and technology, Indication And therapy, Country/Territory, Date, and Company.
- Status filter:** A detailed view of the Status filter showing options like Preclinical, Phase 1 Clinical, Phase 2 Clinical, Phase 3 Clinical, Clinical, Registered, and Pre-registration, each with a count.

Callout boxes provide additional context:

- "Quickly filter for drugs that have specific information" points to the "Drugs with..." dropdown.
- "All Filters section provides filter groups for easier access" points to the "All filters" button and the expanded filter panel.

Drug name	Status	Other drug name	Company
KB-9558	Clinical	N-methyl-2-pyrrolidone N-methylpyrrolidone comp +more	
KB-9558		histone lysine methyltransf	
KB-9558		KB-528 KB-9558	
gint		KTX-1001 KTX-1031 +more	Novartis Pharmaceuticals Corp (US)
KTX-1029	Preclinical	KTX-1029	K36 Therapeutics Inc (US)

New search results page

The screenshot shows the Cortellis search results page for the query "multiple myeloma". The page displays 1,148 drug results. A "Customize columns" dialog is open, showing a list of columns to be displayed in the table. The "Other drug name" column is highlighted with a red box, and a red box around the equals sign indicates it can be deselected or re-arranged. A "Save and alert" dialog is also open, showing alert settings for the search results. The "Save and alert" dialog has a red box around the "Set alert" checkbox and the "Reason for update" section, which includes checkboxes for Chemistry, Development profile, Development status, Drug name, and Index. The "Alert start date" is set to 11/6/2025, and the "Frequency" is set to Daily. The "Recipient Email Address" is robert.provines@clarivate.com. A red box around the "Alert me if no updates" toggle indicates it can be selected or deselected. A "Support" button is visible at the bottom right of the page.

Customize columns

Select all

- Drug name
- Highest status
- Other drug name
- Originator company

Save and alert

Set alert

Reason for update Chemistry Development profile Development status Drug name Index

Format HTML (default) Text

Alert start date: 11/6/2025

Frequency: Daily

Alert me if no updates

Recipient Email Address: robert.provines@clarivate.com

Support

Deselect or re-arrange columns in the table

Select all alert settings in a single window



New Industry Report

New Industry Report*

Forecasts and analysis for major companies, key therapy areas and top products

The screenshot displays the Cortellis website interface. At the top left, the logo "Cortellis" is visible. A search bar contains the text "Search drugs, clinical trials, patents and more" and a "Search" button. Below the search bar, a navigation menu is shown with the "Competitive Intelligence" section expanded. The "Industry Report" option is highlighted in the menu. A callout box points to the "Competitive Intelligence" section with the text "Click to expand the Competitive Intelligence section". Another callout box points to the "Go to Report" button in the "Industry Report" card with the text "Select Industry Report and click Go to Report". The "Industry Report" card contains the following text: "This report covers an overview of the Pharma industry with details at therapy area, major companies, and top products' level providing insights for global, US and ROW (Rest of the World) regions". Other cards visible include "Analysis" and "Next generation Cortellis Competitive Intelligence (Beta)". A "Support" button is located in the bottom right corner.

*depending on your company's subscription

New Industry Report

Industry Overview

Industry Report

Download

Industry Overview

Industry Overview includes an Executive Summary, key themes for the year, and sales and forecasts for the world pharmaceutical market

Executive Summary

- Compared to 2022 (where YoY growth was 7%), the global pharmaceutical industry's* YoY growth will witness a substantial decrease in the sales of COVID-19 vaccines and treatments. In terms of therapy area, the pharmaceutical industry, by contributing the maximum drug brand sales. Other key therapy areas that include Endocrine/Metabolic, Neurology/Psychiatric, Cardiovascular, and Musculoskeletal Pain.
- In addition, Keytruda, Humira, Ozempic, Eliquis, and Biktarvy were the top-selling drug brands in 2023. In 2030, other key contributors are expected to be Mounjaro, Tagrisso, and Ozempic.
- In 2023, AbbVie, Pfizer, Johnson & Johnson and Merck & Co were the top contributors in global ethical drug sales for 2024 will show a growth trend, primarily supported by the United States market.
- Furthermore, amidst the slowdown of global ethical drug sales, the sales from the U.S. market observed a slight decline, while the sales from the ROW market were estimated to plateau.
- Clarivate identifies some underlying themes below, which shaped the biopharmaceutical market in 2023.


The Surge of GLP-1 Agonists Amidst Their Expanding Role in Healthcare

- Traditionally dominated by cancer therapies, this year's top-selling drug brands list witnessed the unexpected rise of Ozempic to the third place. This noteworthy development came on the heels of the meteoric rise of Ozempic's popularity in China. Ozempic, which is also seen as a miracle drug for the treatment of diabetes, provides various health benefits and considerable weight loss (in the range of 12-15%). With obesity reaching epidemic levels across the globe, a market has been created for drugs that can enable rapid weight loss without many side effects. For instance, according to the CDC, over two in five U.S. adults are afflicted with this chronic condition. This presents a significant opportunity for developers of Ozempic, as the drug gained popularity for its treatment efficacy. Further capitalizing on a demand for weight loss drugs, which can provide an alternative to the existing bariatric procedures, Novo Nordisk launched Wegovy.

World Pharmaceutical Market


View

Select by chart type
Sales (USD M)



New Industry Report

Company Overview




Switch to Table View for rankings and additional companies

Top Companies Ranked by Sales in All Countries View 

Company ↑	Rank		Actuals (USD M)					Forecasts (USD M)						CAGR (2023-2030) (%)	
	2023 ↑	2030 ↑	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029		2030
Johnson & Johnson	1	3	38,297	41,842	48,694	50,098	52,573	54,762	56,152	56,729	57,236	59,231	60,348	60,962	2.14
Pfizer Inc	2	6	39,833	33,702	71,000	91,266	51,344	48,183	49,735	51,545	51,244	52,257	54,170	55,580	1.14
AbbVie Inc	3	5	32,755	40,783	51,056	53,628	50,965	50,457	51,441	52,615	54,260	56,184	56,669	56,073	1.37
Merck & Co Inc	4	2	38,709	39,400	40,511	49,586	50,946	54,376	58,170	61,539	65,177	67,320	65,837	63,493	3.2
Roche Holding AG	5	7	46,332	44,266	48,538	47,911	46,600	50,291	52,397	54,119	55,721	56,487	55,972	54,927	2.38


New Industry Report

Therapy Area Overview



New Industry Report

Drug Overview



New Industry Report

Downloads

Industry Report

Download

Industry Overview | Company Overview | Therapy Area Overview | Drug Overview

Select by region
All Countries

Download the Industry Report to Excel, PowerPoint or PDF and select which content to include

Top 10 Drugs Ranked by Sales in All Countries

Actuals | Forecasts

Sales (USD M)

2019 2020 2021 2022 2023 2024 2025 2026 2027

Humira Keytruda Revlimid Eliquis Opdivo Eylea Imbruvica Enbrel Avastin Xarelto Stelara
Biktarvy Comirnaty / BNT-162 Spikevax Paxlovid Ozempic Dupixent Darzalex / Darzalex Faspro
Jardiance family Mounjaro Trikafta / Kaftrio Gardasil/ Gardasil 9 Skyrizi Tagrisso Zepbound

Download

Select the format

Excel Power point PDF

Select

All

Industry Overview

Executive Summary World Pharmaceutical Market

Company Overview

Top Companies Ranked by Sales Company Sales Analysis

Therapy Area Overview

Sales by Therapy Area Leading Therapy Area

Therapeutic Breakdown R&D Contribution to Sales

Therapy Area Sales and Shares by Technology Small Molecule(Chemical) Sales by Therapy Area

Biological Sales by Therapy Area

Cancel Download

New Industry Report

Links to the Industry Report in other locations

metformin	
Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >
Latest Press Releases	SNAPSHOT
Latest Event Transcripts	Drug Name metformin
Broker Research Reports	Other Drug Names LA-6023; metformin hydrochloride; metformin; BMS-207150; SMP-862; Glifage IR; Glucophage; Diabetosan; Diabex; Fluamine; Flumamine; Gliguanid; Metgluco; Glucofit; Metfogamma; Siofor; Diabex XR; Diaformin; Glifage
Development Profile	Originator Company Merck Sante SA
Literature Review	Active Companies Acino Holding AG ; Merck Sante SA ; Bristol Myers Squibb Co ; Daewoong Pharmaceutical Co Ltd ; Sumitomo Pharma Co Ltd ; Merck Serono SA ; Merck KGaA
Development Status	Therapy Area Cancer; Endocrine/Metabolic; Genitourinary/Sexual Function
Regulatory Designations	Inactive Companies Sumitomo Chemical Co Ltd
Milestones	Highest Status Launched (Non-insulin dependent diabetes - France - Dec-1959; Non-insulin dependent diabetes - UK - Dec-1959)
Chemical Structures	Regulatory Designations
Drug Names	Active Indications Anovulation; Stage III melanoma; Stage IV melanoma; Metastatic non small cell lung cancer; Non-insulin dependent diabetes View Epidemiology in IPD
Sales and Forecasts	Inactive Indications
Market Landscape	Target-based Actions AMP activated protein kinase stimulator
Clinical Trials	Other Actions Anticancer; Hypoglycemic agent; Ovulation stimulator; Biguanide antidiabetic product
Deals and Patents	Technologies Oral formulation; Tablet formulation; Film coating; Small molecule
SWOT Analysis	Franchises Diabetes, oral biguanides
Safety Intelligence	EphMRA Codes A10B2 (Biguanide antidiabetics)
Change History	Last Change Date 04-Nov-2025
Sources	Added Date 16-Feb-1996
	Industry Report View Report

AbbVie Inc	
Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >
Latest Press Releases	SNAPSHOT
Latest Event Transcripts	Company Name AbbVie Inc
Broker Research Reports	Parent Company Name AbbVie Inc
Company Profile	Organization Type Organization Type : Pharma Company Type : Public Company Size : Large
Company Insights	Field of Activity Pharmaceuticals ; Biologics
Funding	Private Equity Backed Status
Financials	Website https://www.abbvie.com/
Company Contacts	Country/Territory US
Subsidiary Companies	Number of Drugs In Active Development 277
Drug Sales and Forecasts	Number of Inactive Drugs 689
Drugs	Number of Patents as Owner 6002
Deals	Number of Patents as Third Party 308
Clinical Trials	Number of Deals 1562
Patents	Key Indications Solid tumor ; Ulcerative colitis ; Advanced solid tumor ; Alzheimers disease ; Rheumatoid arthritis ; Crohns disease ; Metastatic non small cell lung cancer ; Parkinsons disease ; Cancer ; Major depressive disorder
Change History	Key Target-based Actions Tubulin polymerization protein inhibitor ; Alpha 2 adrenoceptor agonist ; Estradiol agonist ; Progesterone receptor agonist ; Prostanoid receptor agonist ; LanC like protein 2 stimulator ; Jak1 tyrosine kinase inhibitor ; Topoisomerase I inhibitor ; NMDA receptor partial agonist ; Tubulin modulator
Sources	Key Technologies Small molecule ; Biological ; Oral formulation ; Intravenous formulation ; Antibody drug conjugate ; Infusion ; Drug combination ; Systemic formulation unspecified ; Ophthalmic formulation ; Capsule formulation
	Added Date 30-Aug-2012
	Industry Report View Report

The Industry Report can also be accessed from a Drug or Company Report



Drug Analog Generator

Drug Analog Generator*

Simulate product sales and examine a product's lifecycle

The screenshot displays the Cortellis web application interface. At the top left, the logo "Cortellis" is visible. A search bar contains the text "Search drugs, clinical trials, patents and more" and a "Search" button. Below the search bar, a navigation menu is shown with the "Competitive Intelligence" section highlighted. The main content area features several panels: "Industry Report", "Analysis", and "Next generation Cortellis Competitive Intelligence (Beta)". The "Analysis" panel lists options such as "Competitive landscape viewer", "Drug Attrition Rates", "Drug analog generator", "Competitive intelligence matrix", "Virtual merger", and "Intellectual property landscape". The "Drug analog generator" option is highlighted with a purple box. A callout box points to this option with the text "Select Drug Analog Generator and click Analyze". Below the "Drug analog generator" option, there is an "Analyze" button. The "Next generation Cortellis Competitive Intelligence (Beta)" panel includes a "New" drugs dashboard interface for all competitive intelligence users. A "Support" button is located in the bottom right corner of the interface.

*depending on your company's subscription

Drug Analog Generator

The Drug Analog Generator

[Home](#) [Methodology](#) [Analog Finder](#) [Analog Summary](#) [Sales Simulator](#) [Tool Guide](#)

Analog Generator

The Analog Generator enables identification of analog products with the nearest matching desirable drug parameter to a product of interest. The tool also provides actual reported sales curves for the U.S. along with concise drug annotations. The Drug Analog Generator Includes the following three Tools:

Analog Finder

Create a scenario and select analogs from available drug attributes and sub-attributes.

Select Analog Finder



The Analog Finder allows to choose desired attributes from 19 parameters to model a market scenario and generate analogs.

Analog Summary


Review description for each of the analog selected in the Analog Finder.



The Analog Summary allows for analysis of selected analogs from the Analog Finder tab.

Sales Simulator

Simulate sales for selected analogs and customize output data.



The Sales Simulator is based on tool-generated or user-defined analog(s) use this tool to simulate product sales and market scenario and to obtain the final data output of the analysis.

Drug Analog Generator

Analog Finder

Home Methodology **Analog Finder** Analog Summary Sales Simulator [Tool Guide](#)


Select desired parameter to model a scenario [Reset Filters](#)

The Analog Finder allows you to choose the parameters for a certain scenario. All are selected automatically. De-select some of them to make changes.

- Black Box Warning**
 - Select All
 - No
 - Yes
- Co-Promotion**
 - Select All
 - No
 - Yes
- Dosing Frequency**
 - Select All
 - Annual
 - Biannual
 - Bimonthly
 - Biweekly
 - Daily
 - Monthly
- Dosing Frequency Change**
 - Select All
 - Not Applicable
 - OD to TDS/BD
 - Others
 - TDS/BD to OD
 - Weekly to Monthly
- Drug Technology**
 - Select All
 - Biologics
 - Gene Therapy
 - Other
 - Small Chemical Molecules
 - Synthetic Peptide
 - Vaccine
- Generic/Biosimilar**
 - Select All
 - Genericized
 - Non Genericized
- Launch Timing**
 - Select All
 - Before 2005
 - 2005-2010
 - After 2010
- Lead Indication Approved Age R...**
 - Select All
 - 18 years and above
 - For all age groups
 - Infants
 - Infants+Pediatric
 - Only elderly
 - Pediatric
- Market Type At Product Launch**
 - Select All
 - Branded
 - Generic
 - Mixed
- Mono/Combo Therapy**
 - Select All
 - Combination therapy
 - Monotherapy
 - Monotherapy, Combination therapy
- Order Of Entry**
 - Select All
 - I
 - II
 - III
 - Ivth or later
- Orphan Status**
 - Select All
 - No
 - Yes
- Peak Sales**
 - Select All
 - <\$500mn
 - \$500mn-\$1bn
 - \$1bn-\$5bn
 - >\$5bn
- Reformulation**
 - Select All
 - Injectable to Oral
 - IV to SC
 - Not Applicable
 - Oral to Injectable
 - Others
 - SC to IV
- Route Of Administration**
 - Select All
 - IM
 - Inhaler
 - Injectable Others
 - IV
 - IV+SC
 - Multiple
- Therapy Area**
 - Hematology
 - Metabolism
 - Musculoskeletal_Pain
 - Oncology
 - Ophthalmology
 - Respiratory
- Type Of Lead Indication**
 - Select All
 - Acute
 - Chronic
- Type Of Treatment**
 - Select All
 - Disease curing
 - Maintenance
 - Prophylactic
 - Symptomatic
- Years To Peak**
 - Select All
 - <5 years
 - 5-8 years
 - >8 years

Drug Analog Generator

Analog Finder



Drug Analog Generator

Analog Finder


Parameter Summary

Select Parameter

Orphan Status

The chart below the sales chart shows how many drugs are categorized with each parameter. Use the drop-down to select a parameter.

Orphan Status



Drug Analog Generator

Analog Summary

Home Methodology Analog Finder **Analog Summary** Sales Simulator [Tool Guide](#)

Analog Filter: Nexavar, Provenge, Torisel, Zolozinza
Market Scenario: Product Uptake
Curve Statistics: Actual Shares
Show Value As: Sales in (%)

Product Curves (Sales in %)

Selected Curves	Year Of Launch ↑	Peak Sales Value (Sales in %) ↑	Time To Peak ↑	Y1	Y2	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18	Y19	Y20
Nexavar,Oncology	2005	363.0	10	19	38	53	59	63	66	72	80	89	100										
Provenge,Oncology																							
Torisel,Oncology																							
Zolozinza,Oncology																							

Product Description

Selected Curves: Nexavar (Oncology)

Attribute Name	Attribute Value
Product name	Nexavar
Therapy area	Oncology
Market type	Branded
Order of entry	I
Route of Admin	Oral
Type of Treatment	Maintenance
Launch Timing	2005-2010

Use the drop-downs to modify the settings for the Analog Summary

Click the arrow icons to download data to Excel

Each drug includes the year of launch, peak sales value, the time (in years) to peak sales and the percentage of peak sales achieved in Year 1, Year 2, etc.

View the attributes for individual drugs in the Product Description

Drug Analog Generator

Sales Simulator

Home Methodology Analog Finder Analog Summary **Sales Simulator** [Tool Guide](#)

The Sales Simulator is based on tool-generated or user-defined analogs. Use this tool to simulate product sales and market scenarios AND to obtain the final data output of the analysis.
Important: For tool generated analogs you must select desired parameters in the Analog Finder tab. Otherwise, select a product here to directly apply a user-defined analog
Note: The values (in USD M) shown for the respective curves are not the actual reported sales and are calculated based on the input in "Peak sales" and the actual uptake curve.

Use the drop-downs to modify the settings for the Sales Simulator

Direct Comparator: Abecma (Oncology) | Market Scenario: Product Uptake | Curve Statistics: Actual Shares | Standard Uptake/Erosion Rate: 8 Year Slow | Peak Sales (USD M): Search here | Show Values As: Sales in (%)

Select which direct comparator you would like to compare to your selected analog 1143 | Select the type of market scenario | Select what type of data Statistics to apply to the curve | Select what type of data Statistics to apply to the curve | Input desired peak sales estimate for the sales simulator analysis | Choose to show values as sales in (USD M) or sales in (%)

Product Uptake Curves (Sales in %) Three product uptake curves are displayed, with the percentage of peak sales based on the year after launch

Selected Curves	Y1	Y2	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10	Y11	Y12	Y13	Y14	Y15	Y16	Y17	Y18	Y19	Y20
Simple Avg(of selected products)	31	54	69	70	78	83	88	89	94	100	100									
Abecma	81	100																		
8 Year Slow	5	10	22	40	61	78	90	100												


Simple average of the selected drugs

A single drug, which can be selected with the Direct Comparator drop-down in the upper left

Standard Uptake Rate of 8 Year Slow, which can be changed in the related drop-down above

Drug Analog Generator

Sales Simulator



Thanks for joining.

You can login and run your own searches from [this link](#)

robert.provines@clarivate.com

Senior Customer Education Specialist

Clarivate